Salute e Benessere

Full-Year 2024 Results - Progress on the implementation of the FOCUS-27 plan…

Press Release Paris, 3 rdMarch, 2025Full-year 2024 results 1 : Operational resilience and strong increase in Free Cash Flow before financing in a challenging environment Net sales down 10.0% to €911.9 million, driven by lower volumes for Sanofi and the suspension of production at Brindisi, only partly offset by encouraging commercial momentumCore EBITDA at €50.4m, with margin down 370bps year-on-year to 5.5%, due notably to unfavorable fixed cost impact€(43...
Nasdaq GlobeNewswire
03/03/2025

Parenteral Nutrition Market Size to Hit $11.12 Billion, Globally, by 2030 |…

Parenteral Nutrition Market Overview of Report Findings Parenteral Nutrition Market Overview of Report Findings For Detailed Parenteral Nutrition Market Insights, Visit: https://www.theinsightpartners.com/reports/parenteral-nutrition-market Competitive Strategy and Development Key Players : Major companies operating in the parenteral nutrition market are Trending Topics : Vitamins & minerals, intravenous nutritional products, dehydration, and electrolyte...
PR Newswire
03/03/2025

Zelluna ASA [ZLNA]: The first ever cell therapy company to list on the Oslo…

The share capital increases relating to the issuance of the Consideration Shares and the Private Placement Shares was registered today on 3 March 2025 with the Norwegian Register of Business Enterprises. The new share capital of the Company is now NOK 20,227,065.30 divided into 202,270,653 shares, each with a nominal value of NOK 0.10. Consequently, the Business Combination has now been completed.The name change from Ultimovacs ASA to Zelluna ASA has also been registered with the Norwegian...
Nasdaq GlobeNewswire
03/03/2025

Biopsy Devices Market worth US$11.01 billion by 2030 with 7.2% CAGR |…

Browse in-depth TOC on "Biopsy Devices Market"170 - Tables70 - Figures300 - Pages Browse in-depth TOC on "Biopsy Devices Market" 170 - Tables 70 - Figures 300 - Pages By product type,the biopsy devices market is divided into Needle based biopsy instrument, Visualization device, Brush biopsy instrument, Biopsy accessory and robotic biopsy device. Among these, in 2023, the biopsy accessory segment accounted for the second highest market share in the biopsy device market...
PR Newswire
03/03/2025

ABM of PPC Inc. Unveils the World's First Emotion Processing Unit (EPU) Chip: A…

The ABM team has direct relationships and communication points of contact with various organizations across Academia (Boston University, Georgia Tech, Harvard University, UCLA, Yale, etc.); Commercial and Government Contractors (General Dynamics, Lockheed, Northrop Grumman, Raytheon, etc.); and multiple U.S. Government and Military agencies and organizations (DARPA, U.S. Army Battle Labs, U.S. Intelligence Community, etc.) These relationships provide ABM multiple collaborative and joint venture…
PR Newswire
03/03/2025

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities…

ORION CORPORATIONSTOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 3 March 2025 at 16.30 EET Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly, indirectly and through financial instruments by BlackRock, Inc. and its funds increased on 28 February 2025...
Nasdaq GlobeNewswire
03/03/2025

Renovaro Completes First Milestone Payment to Finalize Definitive Agreement with…

Company Commits the First Tranche of Financing to Initiate the Integration of AI/ML Platform Technologies, Core Laboratory Capabilities and Business Development Efforts in Europe and the United StatesRenovaro's Strategic Acquisition of BioSymetrics Vastly Expands Biomarker and Drug Discovery Opportunities and the Development of Diagnostic Applications in Oncology LOS ANGELES, March03, 2025(GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ: RENB), a TechBio leader focused on...
Nasdaq GlobeNewswire
03/03/2025

Coronado Research Announce the Appointment of Stephen Ralston as EVP Market…

Within his new role at Coronado Research, Stephen will help customers navigate the complexities of the industry while ensuring the delivery of high-quality, impactful solutions, using his unique understanding of the challenges clients face in developing strategies and evidence for new assets. Within his new role at Coronado Research, Stephen will help customers navigate the complexities of the industry while ensuring the delivery of high-quality, impactful solutions, using his unique...
PR Newswire
03/03/2025

Callio Therapeutics Launches with US$187 Million Series A to Advance…

"We are delighted to be launching Callio Therapeutics with the support of Frazier Life Sciences and this syndicate of investors. Multi-payload ADCs have the potential to enable the targeted delivery of rational drug combinations to cancer cells, and may provide significantly enhanced efficacy," said Piers Ingram, PhD, co-founder and Chief Executive Officer of Callio Therapeutics. "This new generation of ADC therapies may meaningfully improve outcomes for patients." "We…
PR Newswire
03/03/2025

DrFirst Recognized for Enabling Technology Leadership in Healthcare by Frost &…

The U.S. healthcare market has long struggled with entrenched resistance to change, resulting in isolated healthcare information systems that hinder collaboration. Limited interoperability has led to inefficiencies, medication errors, and unnecessary hospital readmissions. In response to these challenges, DrFirst has developed a holistic, technology-driven approach that empowers healthcare professionals and patients with real-time access to accurate patient information, enhancing decision-making…
PR Newswire
03/03/2025

Trading by management and close relations of management

In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novonesis reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B.Please see attached the full announcement. Attachment 2025_05_Trading_By_Management
Nasdaq GlobeNewswire
03/03/2025

Kanazawa University Research: Kanazawa University Invites Industry Collaboration…

Advancing Industry Innovation with Bio-SPM TechnologyWPI-NanoLSI is dedicated to driving progress in nano-life sciences by advancing Bio-SPM technologies, including atomic resolution and 3D-AFM, high-speed AFM, scanning ion conductance microscopy (SICM), and cell measurement AFM. These techniques enable unprecedented visualization of dynamic biological and material phenomena at the nanoscale.Through this collaboration, industry researchers and engineers will have the opportunity to work…
PR Newswire
03/03/2025

HANZA completes billion SEK acquisition - broadens customer base and strengthens…

HANZA's acquisition strategy is based on identifying financially stable companies with a strong corporate culture and complementary expertise. The acquisition is part of the "HANZA 2025" strategy, which aims to expand the business in existing geographies and technologies in Europe. HANZA's acquisition strategy is based on identifying financially stable companies with a strong corporate culture and complementary expertise. The acquisition is part of the "HANZA 2025" strategy…
PR Newswire
03/03/2025

Novo Holdings and TA Associates partner with Biocomposites to drive next chapter…

Headquartered in Keele, United Kingdom, Biocomposites' pioneering calcium compounds and specialty polymer products – including STIMULAN, the only calcium matrix carrier platform approved to carry antibiotics into infected and non-infected sites in bone and soft tissue – are trusted by surgeons in over 100 countries worldwide. With over 30 years of expertise, Biocomposites' advanced solutions are used in more than one million procedures annually, across multiple specialties including…
PR Newswire
03/03/2025

Therapeutic Goods Administration decides not to register lecanemab in Australia

"We are very disappointed with the TGA's decision. Foremost it is sad for all patients, caregivers and healthcare professionals in Australia who will now have to wait longer for a treatment which can effectively change the course of this devastating disease. We know that for these patients, time is what they value the most and denying them a treatment which has been shown to delay the onset of more severe stages of the diseases is of course not what they or we had hoped for," said…
PR Newswire
03/03/2025

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial…

Attachments Notification of managers' transaction - Anthony Rosenberg - Feb 2025 RSU vestNotification of managers' transaction - Arshad Khanani - Feb 2025 RSU vest
Nasdaq GlobeNewswire
03/03/2025

Essity's Annual Report for 2024

Read the complete CEO message and about Essity's strategic priorities, earnings and leading sustainability work in the Annual Report for 2024, which is attached to this press release and can be downloaded at essity.com. Read the complete CEO message and about Essity's strategic priorities, earnings and leading sustainability work in the Annual Report for 2024, which is attached to this press release and can be downloaded atessity.com. NB:This is information that Essity is obliged to...
PR Newswire
03/03/2025

The 91st CMEF to Unveil Latest Trends in Medical Device Industry

Since its launch in 1979, the biannual CMEF has evolved into the global medical technology industry's most comprehensive platform, integrating technological innovation, product launches, business networking, brand promotion, academic exchange, and trend analysis. The 91 edition will feature industry leaders including United Imaging, GE Healthcare, Mindray, Philips, Shinva, Yuwell, and China National Medical Device, presenting tens of thousands of products alongside global premieres, underscoring…
PR Newswire
03/03/2025

Nicox Presents New Analysis from the NCX 470 Mont Blanc Trial and Provides…

Press ReleaseNicox Presents New Analysis from the NCX 470 Mont Blanc Trial and Provides Development Update More patients on NCX 470 achieve an intraocular pressure (IOP) of less than or equal to 18 mmHg compared to latanoprostNew analysis provides additional data demonstrating differentiation of NCX 470Development activities on track for U.S. New Drug Application submission targeted in H1 2026March 3, 2025 – release at 7:30 am CETSophia Antipolis, France ...
Nasdaq GlobeNewswire
03/03/2025

Arcadis awarded lead design role for QEII Halifax Infirmary Expansion Project

The 1.2M sq. ft. state-of-the-art acute care facility will usher in a new era of healthcare delivery in the province and will feature 216 inpatient beds,16 cutting-edge operating theatres, a new intensive care unit, and a larger emergency department. Designed and constructed on the existing site, the new facility will seamlessly integrate with the current hospital's facilities. The project will minimize disruptions to ongoing hospital operations while addressing the province's critical…
PR Newswire
03/03/2025

Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare…

Saint-Herblain (France), March 3, 2025–Valneva SE(Nasdaq: VALN; Euronext Paris: VLA) a specialty vaccine company, today announced that its senior management will participate at upcoming investor conferences in the United States and Europe. CEO Thomas Lingelbach and CFO Peter Bühler will present at the TD Cowen 45th Annual Health Care Conference, taking place March 3 - 5, 2025, in Boston, MA. Mr. Lingelbach and Mr. Peter Bühler will also meet with institutional investors during the Van...
Nasdaq GlobeNewswire
03/03/2025

Pulnovo Medical Announces Closing of Nearly $100 Million Series C Financing

Founded in 2013, Pulnovo Medical is a pioneering medtech company recognized in international guidelines. The company leverages its extensive clinical expertise to drive scientific advancements and global commercialization. The company focuses on developing superior therapeutic solutions for various stages of HF to enhance patient outcomes. Founded in 2013, Pulnovo Medical is a pioneering medtech company recognized in international guidelines. The company leverages its extensive clinical...
PR Newswire
03/03/2025

Phase III study shows Xolair may be more effective with fewer side effects than…

First-ever head-to-head trial comparing Xolair and oral immunotherapy (OIT) Results were featured as late-breakers at the 2025 AAAAI Annual MeetingXolair is the only US FDA-approved medicine to reduce allergic reactions in children and adults with one or more food allergiesBasel, 2 March 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new positive data from Stage 2 and Stage 3 of the National Institutes of Health (NIH)-sponsored phase III OUtMATCH study, which provide...
Nasdaq GlobeNewswire
02/03/2025

EMSRUN Medical Strengthens Middle East Footprint with Innovative Emergency Care…

EMSRUN has distinguished itself as the only Chinese company certified by the Saudi Food and Drug Authority (SFDA), a crucial endorsement for marketing pharmaceutical products in Saudi Arabia. This certification highlights EMSRUN's commitment to international quality and technical standards and facilitates expedited market entry and sales across the region. EMSRUN has distinguished itself as the only Chinese company certified by the Saudi Food and Drug Authority (SFDA), a crucial endorsement…
PR Newswire
01/03/2025
Altri  Comunicati